December 4, 2013
Ono Pharmaceutical will make inroads into the Japanese market of sodium-glucose co-transporter-2 (SGLT-2) inhibitors as a copromotor of dapagliflozin, which was jointly developed by AstraZeneca K.K. and Bristol-Myers K.K., the three companies said on December 3. Ono inked a copromotion...read more